Topline data from the Phase III ALIGN study showed that Novartis’ investigational endothelin A receptor antagonist atrasentan met its primary endpoint, significantly reducing protein in the urine of patients with IgA nephropathy,… Read More
Up to 60,000 patients in the United States may have PPF, with only one approved therapy available SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C. — United Therapeutics Corporation (Nasdaq: UTHR),… Read More
A new study from researchers at UBC’s Faculty of Medicine reveals a direct link between high insulin levels, common among patients with obesity and type 2 diabetes, and pancreatic cancer…. Read More
VANCOUVER, BC — AbCellera (Nasdaq: ABCL) announced that executives from the Company will present at the Jefferies London Healthcare Conference on Tuesday, November 14, 2023, at 4:30 p.m. Greenwich Mean… Read More
LONDON, ON; WINDHAM COUNTY, Connecticut — Sernova Corp. (TSX:SVA) (OTCQB:SEOVF) (FSE/XETRA:PSH), a clinical-stage company and leader in cell therapeutics, announced an update on its conformal coating immune protection technology program,… Read More
